mySugr Diabetes Logbook app (mySugr GmbH)
9 June 2016. A clinical center specializing in metabolic disorders is collaborating with a designer of mobile diabetes software on research to upgrade and enhance the company’s apps. Financial terms of the agreement between Profil Institute for Clinical Research in Chula Vista, California and mySugr GmbH in Vienna, Austria were not disclosed.
The company mySugr GmbH offers mobile and Web apps to help people with diabetes manage their condition and ease the constant, tedious collection of data. It’s lead product is mySugr Diabetes Logbook, offered in Apple iOS and Android versions, which the company says has more than 700,000 users. The mobile app aims to make it easier for people with diabetes to collect the various pieces of information, such as food consumed, directly from its users. The app (iOS version) also connects directly to blood glucose meters to capture data from those devices.
The logbook app analyzes the collected data and returns charts with blood glucose levels and estimates HbA1c, or glycated hemoglobin, that provides average blood sugar levels over specified time periods. In addition, the app offers feedback and challenges to keep users motivated, and as the company motto claims, to “make diabetes suck less.”
The Profil Institute is a clinical research center that specializes in metabolic disorders including diabetes, obesity, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis, or NASH. The company conducts early- and intermediate-stage clinical trials for pharmaceutical and medical device companies in preparation for regulatory filings. Profil Institute says it completed some 280 clinical studies covering every relevant drug class in diabetes.
The agreement calls for Profil Institute and mySugr to partner on studies building clinical evidence that support further development of mobile apps dealing with diabetes. Frank Westermann, CEO of mySugr, notes in a joint statement that “digital diabetes therapy still lacks a clear clinical interpretation of the vast amount of data generated. We need to better understand the exact impact of digital tools by examining evidence-based outcomes to determine where we can add even more value to diabetes therapy.”
Profil Institute Chairman and CEO Marcus Hompesch adds, “Clinical data from well-designed studies will be crucial in demonstrating the impact of digital health on health outcomes, resulting in greater opportunities for mobile apps to be useful for broader medical care situations.”
Read more:
- Sanofi Adopting Big Data for Diabetes Drug Adherence
- Diabetes Biotech Acquires GSK Spin-Off
- Sanofi, Google to Partner on Diabetes Care, Devices
- Glucose Control Implant Bests Diabetes Drug in Trial
- Mobile Diabetes Device Maker Lands $20M in Venture Funds
* * *
RSS - Posts
You must be logged in to post a comment.